Abstract
BackgroundThe relationship between oral activated charcoal (OAC) and hyperphosphatemia and vascular calcification is not completely clear. We observed and recorded the effects of OAC on hyperphosphatemia and vascular calcification in stage 3–4 chronic kidney disease (CKD).MethodsIn a randomized controlled study, we included 97 patients with stage 3–4 CKD. In the first phase of the experiment, the patients were randomly divided into the OAC group and placebo group. The endpoint of this phase was the development of hyperphosphatemia. The patients with hyperphosphatemia were selected into the second phase of the study. These patients underwent coronary artery multidetector computed tomography (MDCT) and were randomly divided into three groups: the OAC group, the calcium carbonate (CC) group and the lanthanum carbonate (LC) group.ResultsThe first and second phases of the experiment were followed for 12 months. In the first phase of the experiment, there was a statistically significant difference in the proportion of patients with hyperphosphatemia between the OAC and placebo groups (28.57% vs. 79.17%, X2 = 24.958, P = 0.000). In the second phase, the differences in coronary calcification score (CACS) between the OAC group, the CC group and the LC group were statistically significant (525.5 ± 104.2 vs 688.1 ± 183.7 vs 431.4 ± 122.5, P < 0.01).ConclusionOral activated charcoal effectively delays the onset of hyperphosphatemia in patients with chronic kidney disease. OAC appears to delay the development of vascular calcifications in stage 3–4 CKD patients.
Highlights
In recent years, chronic kidney disease (CKD) has become a worldwide public health issue [1]
Activated charcoal is widely used as an adsorbent in many fields, but there is little research regarding the preventive effect of medical charcoal on hyperphosphatemia and vascular calcification in stage 3–4 CKD patients with normal serum calcium and phosphorus levels
Patients with hyperphosphatemia were selected to enter the second phase of the study, during which we studied the impact of three different phosphate binder strategies on coronary calcification
Summary
Chronic kidney disease (CKD) has become a worldwide public health issue [1]. We observed and recorded the effects of OAC on hyperphosphatemia and vascular calcification in stage 3–4 chronic kidney disease (CKD). In the first phase of the experiment, the patients were randomly divided into the OAC group and placebo group. The endpoint of this phase was the development of hyperphosphatemia. In the first phase of the experiment, there was a statistically significant difference in the proportion of patients with hyperphosphatemia between the OAC and placebo groups (28.57% vs 79.17%, X2 = 24.958, P = 0.000). Conclusion Oral activated charcoal effectively delays the onset of hyperphosphatemia in patients with chronic kidney disease. OAC appears to delay the development of vascular calcifications in stage 3–4 CKD patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
